风眩方联合西药治疗肝阳上亢型原发性高血压患者的临床疗效观察

中华养生保健 ›› 2024, Vol. 42 ›› Issue (3): 4-7.

风眩方联合西药治疗肝阳上亢型原发性高血压患者的临床疗效观察

王瑞¹, 聂谦^1,2, 谢文^1,2,*

1.成都中医药大学临床医学院,四川成都,610075;
2.成都中医药大学附属医院心内科,四川成都,610032

出版日期:2024-02-01 发布日期:2024-01-23
通讯作者: ^*谢文,E-mail：doctorxiewen2008@sohu.com。
作者简介:王瑞（1997—）,女,回族,籍贯：甘肃省平凉市,硕士研究生在读,研究方向：中西医结合防治心血管疾病。
基金资助:
四川省科技厅项目（2022YFSO395）：四川省中医药管理局项目（2023MS522）：四川省中医药管理局项目（2023MS193）

Clinical Observation of Fengxuan Decoction Combined with Western Medicine in the Treatment of Hyperactivity of Liver Yang in Patients with Essential Hypertension

WANG Rui¹, NIE Qian^1,2, XIE Wen^1,2,*

1. School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan 610075, China;
2. Department of Cardiology, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan 610032, China

Online:2024-02-01 Published:2024-01-23

摘要/Abstract

摘要： 目的探讨自拟风眩方联合西药治疗肝阳上亢型原发性高血压的临床疗效评估。方法选取2020年10月—2022年9月成都中医药大学附属医院收治的原发性高血压病患者100例,根据随机数表法分为研究组和对照组,每组50例。对照组予以常规西药进行治疗,研究组施以风眩方联合常规西药治疗,12周后,对两组患者治疗总有效率、不良反应发生情况及治疗前后24 h平均血压水平进行比较。结果研究组治疗总有效率高于对照组,差异有统计学意义（P<0.05）。治疗前,两组24 h平均收缩压和平均舒张压比较,差异无统计学意义（P>0.05）;治疗后,研究组24 h平均收缩压和平均舒张压均低于对照组,差异有统计学意义（P<0.05）。两组不良反应发生率比较,差异无统计学意义（P>0.05）。结论在常规西药治疗的基础上加入自拟风眩方治疗肝阳上亢型原发性高血压可显著提高降压的有效率和降压幅度,适用于临床。

关键词: 风眩方, 原发性高血压病, 中西医结合疗法

Abstract: Objective Exploring the clinical efficacy evaluation of self-made Fengxuan Formula cooperate with Western medicine in the treatment of primary hypertension with liver yang hyperactivity type. Methods From October 2020 to September 2022, 100 patients with primary hypertension who met the criteria Chengdu University of TCM Cardiovascular Department 2 Outpatient were assigned into research group and control group on the basis of the table of random number, 50 cases were fit into each group. The control group was given Western medicine, and another was grant Fengxuan Decoction combined with conventional Western medicine. After 12 weeks, Compare total effective rate,Side effects and 24-hour mean blood pressure level of the two groups. Results Before treatment,there was no statistically significant difference in 24-hour average systolic and diastolic blood pressure between the study group and the control group (P>0.05). After treatment, the total effective rate of the study group was significantly higher than that of the control group, and the result was statistically significant (P<0.05). The 24-hour ambulatory blood pressure systolic and diastolic blood pressure of the study group were lower than those of the control group.Relatively statistically significant (P<0.05). There was no significant difference in adverse reactions incidence rate between the two groups (P>0.05). Conclusion on the foundatin of Western medicine, adding self-made Fengxuan Decoction in the treatment of primary hypertension with hyperactivity of liver yang can notable improve the effective rate and amplitude of blood pressure reduction, which can be applied to clinical practice.

Key words: FengXuan Prescription, eessential hypertension, integrated Chinese and Western medicine therapy

中图分类号:

R259

王瑞, 聂谦, 谢文. 风眩方联合西药治疗肝阳上亢型原发性高血压患者的临床疗效观察[J]. 中华养生保健, 2024, 42(3): 4-7.

WANG Rui, NIE Qian, XIE Wen. Clinical Observation of Fengxuan Decoction Combined with Western Medicine in the Treatment of Hyperactivity of Liver Yang in Patients with Essential Hypertension[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(3): 4-7.

参考文献

[1] MILLS K T, STEFANESCU A, HE J.The global epidemiology of hypertension[J]. Nat Rev Nephrol,2020,16(4):223-237.
[2] CHIRINOS J A, SEGERS P, HUGHES T, et al.Large-Artery Stiffness in Health and Disease: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2019,74(9):1237-1263.
[3] 《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗原发性高血压临床应用指南(2021年)[J].中国中西医结合杂志,2022,42(7):773-781.
[4] 刘璠,丁秀婷.高血压药物治疗方式及常用药物研究进展[J].中国药业,2015,24(23):253-255.
[5] 中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[6] 周英信,杨德全.中医内科学[M].北京:中国中医药出版社,2018:122.
[7] BARQUERA S, PEDROZA-TOBÍAS A, MEDINA C, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease[J]. Arch Med Res, 2015,46(5):328-338.
[8] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2020概要[J].中国循环杂志,2021,36(6):521-545.
[9] 徐婷,王微.川牛膝水煎液对自发性高血压大鼠血压和左心室肥厚的影响[J].长春中医药大学学报,2008,(4):367,471.
[10] 徐婷. 川牛膝水煎液对自发性高血压大鼠体内SOD水平的影响[J].长春中医药大学学报,2014,30(1):18-19.
[11] 田晓伟,马闻.中药利尿药和西药利尿药在高血压中的应用研究[J].中国继续医学教育,2017,9(4):201-203.
[12] 耿放,孙虔,杨莉,等.车前子与车前草利尿作用研究[J].上海中医药杂志,2009,43(8):72-74.
[13] ZHANG X, LI X Y, LIN N, et al.Diuretic Activity of Compatible Triterpene Components of Alismatis rhizoma[J]. Molecules,2017,22(9):1459.
[14] 邓雨,于思明,陈瑞艳.车前子降尿酸作用机制研究进展[J].新医学,2022,53(9):635-638.
[15] 童仁超. 车前子总苷降糖、降压药效与作用机制研究[D].上海:上海中医药大学,2021.
[16] 兰继平,张洁玉,童仁超,等.车前子对原发性高血压大鼠的降压作用[J].中成药,2020,42(8):2037-2042.
[17] 赵伶俐,曲华,高铸烨.基于网络药理学与分子对接技术探讨益母草干预高血压的作用机制[J].中西医结合心脑血管病杂志,2022,20(24):4446-4451.
[18] 周雪. 蒙药白益母草干预自发性高血压大鼠血管重构的机制研究[D].北京:中央民族大学,2023.
[19] 陈晓兴,朱勇.白芍总苷对胰岛素抵抗模型大鼠高血糖高血压作用分析[J].内蒙古中医药,2013,32(32):37-39.
[20] LI X, SUN C, ZHANG J, et al.Protective effects of paeoniflorin on cardiovascular diseases: A pharmacological and mechanistic overview[J]. Front Pharmacol,2023,14:1122969.
[21] 黑爱连,孙颂三.黄芩甙对大鼠主动脉条收缩的影响[J].首都医科大学学报,1997,18(2):16-19.
[22] 瞿晶田,王家龙,王玉明.黄芩素通过促进内皮细胞eNOS蛋白表达与NO释放增强乙酰胆碱对血管的舒张作用[J].辽宁中医杂志,2019,46(11):2396-2398.
[23] 朱贝贝.基于ACE-AngII-AT1R通路地龙蛋白抑制自发性高血压大鼠血管重塑作用研究[Z].甘肃省,甘肃中医药大学,2020-06-23.